Recursion
@RecursionPharma
Decoding biology to radically improve lives. The industrial revolution of drug discovery is here.
A new feature in @pharmaphorum gets behind the buzzwords to look at what’s needed – namely, data quality, team culture, and clinical execution – to truly shift to an AI-led approach to developing new cancer drugs across the industry. 💡 A few key insights: 🔹 Drug discovery…
Act boldly, with integrity. In a recent video for our internal Recursion University (RXU) series, co-founder and CEO @RecursionChris illustrates the importance of one of our core values – act boldly, with integrity. Launched in 2024, RXU is a platform for both new and tenured…
✨Live from ICML! Researchers from @valence_ai – Recursion’s AI research engine – had a great time sharing our ML breakthroughs at @icmlconf last week in posters and presentations, including: 🔹 The Phenom-2 foundation model paper, our largest foundation model for cell…
In an industry where over 90% of drug candidates fail, we are relentlessly working to find a better way to discover and develop new medicines. A new feature in @WIRED from @vero_greenwood captures the high-stakes world of drug discovery, highlighting the progress we're making,…
🚀 How TechBio is transforming drug discovery with data, AI and compute. @erikdoug, VP of Product at Recursion, will present onstage at @Ai4Conferences happening Aug. 11-13 at the MGM Grand in Las Vegas. He presents Aug. 12, 2025, 2:10pm. ▪️ In the talk, Erik will share what’s…
Empowering the next generation of data scientists. On July 10, as part of London Data Week 2025, the Knowledge Quarter is hosting Future Paths in Data Science – an event designed to offer practical insights and opportunities to students and early-career scientists. Presented…
✨Check out our latest ML advances at #ICML! Researchers from @valence_ai – Recursion’s AI research engine – will be presenting at the @icmlconf in Vancouver, Canada from July 13-19. 🔹 We’ll be presenting 2 ML papers and speaking at one workshop: 📎 PAPER 1: Phenom-2…
Recursion today announced the acquisition of full rights to the REV102 program from Rallybio. REV102 is a potential first-in-class oral ENPP1 inhibitor for the rare genetic disorder Hypophosphatasia (HPP). Learn more: ir.recursion.com/news-releases/…
Last week, Recursion CFO Ben Taylor and Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD spoke with Peter Lawson, a biotech analyst at @Barclays. They discussed Recursion’s 3 main areas of differentiation (end-to-end platform, proprietary data, and wet lab-dry lab…
We had a great turnout for the 2025 Molecular Machine Learning Conference (#MoML) at @Mila_Quebec. Sponsored by Recursion and @valence_ai along with Genesis Therapeutics and Braidwell, the annual event convenes researchers from academia and industry to discuss how ML methods can…
Two weeks ago, @KellyZalocusky, Senior Director of Computational Biology at Recursion and site lead for our London office, joined a panel at London Tech Week to discuss “AI in Action.” The discussion – which featured moderator Sara El-Hanfy, Head of AI & ML at @innovateuk, along…
“When you see the power of these technology tools, it makes it really hard not to feel like there’s going to be an exponential shift in this field.” Recently, cofounder and CEO @RecursionChris sat down with David Bearss, cofounder and CEO of @Halia_Tx and host of the Good…
Using AI to unlock new possibilities in clinical research and improve patient outcomes. Recursion has joined the Council for Responsible Use of AI in Clinical Trials, launched today from @advarra, along with leaders from @sanofi and Velocity Clinical Research, Inc., to drive…
Last week, Recursion CFO Ben Taylor spoke with Salveen Richter, biotech analyst at @GoldmanSachs at the Goldman Sachs 46th Annual Healthcare Conference in Miami. They discussed validation points for the Recursion Operating System, pipeline advances, and how we drive value from…
Join us at BIO! On Tues., June 17, -2:45pm ET, Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD will present at the @IAmBiotech International Convention in Boston on the panel “Computational Drug Design: Benchmarking Bold Bets, Breakthroughs, and…
